EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy

Clin Lung Cancer. 2014 Sep;15(5):387-9. doi: 10.1016/j.cllc.2014.04.005. Epub 2014 May 15.

Authors

Seerat Poonia¹, Eamon M Berge², Dara L Aisner³, Denise Damek², Robert C Doebele⁴

Affiliations

¹ School of Medicine, University of Colorado School of Medicine, Aurora, CO.
² Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
³ Department of Pathology, University of Colorado School of Medicine, Aurora, CO.
⁴ Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. Electronic address: robert.doebele@ucdenver.edu.

No abstract available

Keywords: EGFR; Erlotinib; Leptomeningeal; Miliary nodules; Non–small-cell lung cancer.

Publication types

Case Reports

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Cognition Disorders / drug therapy
Cognition Disorders / etiology
Dose-Response Relationship, Drug
ErbB Receptors / genetics*
Erlotinib Hydrochloride
Exons
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Male
Meningeal Carcinomatosis / genetics
Meningeal Carcinomatosis / pathology
Meningeal Carcinomatosis / secondary*
Middle Aged
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / therapeutic use
Quinazolines / administration & dosage
Quinazolines / therapeutic use
Sequence Deletion
Treatment Outcome

Substances

Protein Kinase Inhibitors
Quinazolines
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors

Grants and funding

K12 CA086913/CA/NCI NIH HHS/United States